We began our journey in areas such as the central nervous system and the eye, where fewer cells are required and immune responses are less likely—making them ideal for cell transplantation. As our iPS cell differentiation technologies have advanced, we are now expanding into more complex areas, including peripheral organs, where medical needs are high and therapeutic possibilities are growing.

Japan is the birthplace of iPS cell technology and offers a rich ecosystem for stem cell research and clinical application. With a dedicated regulatory pathway for regenerative medicine, Japan enables early practical use of these therapies.
Our strategy is to first achieve success in Japan, then expand globally—especially to markets like the United States—so we can bring regenerative medicine to more patients and grow our business internationally.

Cell therapies range from single-cell products to complex 3D tissues and organs. Single-cell therapies are easier to produce and manage, and are effective for diseases affecting specific cell types.
For more complex conditions, we are developing advanced tissue structures using technologies like organoids. These therapies require overcoming technical challenges but offer broader applications and greater impact.
We currently focus on allogeneic transplantation, using iPS cells derived from healthy donors to create high-quality cell therapy products. Looking ahead, we are exploring:

Autologous transplantation, using a patient’s own iPS cells for personalized treatment
Next-generation cell therapies, enhanced through genome editing technologies.